|国家预印本平台
首页|Transforming inert cycloalkanes into alpha-omega-diamines through designed enzymatic cascade catalysis

Transforming inert cycloalkanes into alpha-omega-diamines through designed enzymatic cascade catalysis

Transforming inert cycloalkanes into alpha-omega-diamines through designed enzymatic cascade catalysis

来源:bioRxiv_logobioRxiv
英文摘要

Aliphatic alpha-omega-diamines (DAs) are important monomer precursors in polyamide plastic manufacturing. However, the dominant industrial process for DA synthesis involves energy-intensive, multistage chemical reactions that are harmful to the environment. For instance, 1,6-hexanediamine (HMD), one of most prominent monomers in nylon-66 synthesis, is mainly synthesized with currently high technological control by butadiene hydrocyanation, which suffers from the use of highly toxic hydrogen cyanide, unsatisfactory selectivity and a complex separation process. Thus, the development of sustainable green DA synthetic routes is highly desired. Herein, we report an efficient one-pot in vivo biocatalytic cascade for the transformation of cycloalkanes into DAs with the aid of advanced techniques, including the RetroBioCat tool for biocatalytic route design, enzyme mining for finding appropriate enzymes and microbial consortia construction for efficient pathway assembly. As a result, DAs are successfully produced by the developed microbial consortia-based biocatalytic system, especially HMD, and product concentrations as high as 16.5 mM and 7.6 mM are achieved when using cyclohexanol (CHOL) or cyclohexane (CH) as substrates, respectively. This also represents the highest HMD biosynthesis productivity to date. Other cycloalkanes also serve as substrates, indicating the generality of our approach.

Fang Ling、Jiang Zhengbing、Wang Fei、Li Aitao、Deng Yu、Zhang Zhongwei

10.1101/2022.11.15.516597

生物工程学有机化学工业高分子化合物工业

Fang Ling,Jiang Zhengbing,Wang Fei,Li Aitao,Deng Yu,Zhang Zhongwei.Transforming inert cycloalkanes into alpha-omega-diamines through designed enzymatic cascade catalysis[EB/OL].(2025-03-28)[2025-08-02].https://www.biorxiv.org/content/10.1101/2022.11.15.516597.点此复制

评论